Cargando…

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)

The purpose of this study was to evaluate the efficacy of gefitinib and the feasibility of screening for epidermal growth factor receptor (EGFR) mutations among select patients with advanced non-small cell lung cancer (NSCLC). Stage IIIB/IV NSCLC, chemotherapy-naive patients or patients with recurre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tamura, K, Okamoto, I, Kashii, T, Negoro, S, Hirashima, T, Kudoh, S, Ichinose, Y, Ebi, N, Shibata, K, Nishimura, T, Katakami, N, Sawa, T, Shimizu, E, Fukuoka, J, Satoh, T, Fukuoka, M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2266849/ https://www.ncbi.nlm.nih.gov/pubmed/18283321 http://dx.doi.org/10.1038/sj.bjc.6604249

Ejemplares similares

Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803)
por: Yamamoto, N, et al.
Publicado: (2004)

Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer
por: Negoro, S, et al.
Publicado: (2003)

Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer.
por: Matsui, K., et al.
Publicado: (1998)

A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group.
por: Masuda, N., et al.
Publicado: (1998)

Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer
por: Yamada, M, et al.
Publicado: (2002)

A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B(12) in Japanese patients with solid tumours
por: Nakagawa, K, et al.
Publicado: (2006)

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
por: Asahina, H, et al.
Publicado: (2006)

Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer
por: Takeda, K, et al.
Publicado: (1999)

Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer.
por: Masuda, N., et al.
Publicado: (1993)

Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin.
por: Matsui, K., et al.
Publicado: (1996)

Relationship between the Pharmacokinetics of Irinotecan and Diarrhea during Combination Chemotherapy with Cisplatin
por: Kudoh, Shinzoh, et al.
Publicado: (1995)

Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status
por: Akashi, Y, et al.
Publicado: (2008)

CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer.
por: Fukuoka, M., et al.
Publicado: (1997)

Interleukin 6 is a cause of flu-like symptoms in treatment with a deoxycytidine analogue.
por: Masuda, N., et al.
Publicado: (1998)

P04.03. Primary care providers’ attitudes and beliefs about, and personal use of, complementary and alternative medicine (CAM)
por: George, M, et al.
Publicado: (2012)

Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA)
por: Kokubo, Y, et al.
Publicado: (2005)

Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702
por: Okamoto, H, et al.
Publicado: (2007)

Proteomic Biomarkers for Acute Interstitial Lung Disease in Gefitinib-Treated Japanese Lung Cancer Patients
por: Nyberg, Fredrik, et al.
Publicado: (2011)

OA04.03. Neural responses to the mechanical characteristics of a spinal manipulation: effect of varying direction of the applied thrust force
por: Pickar, J, et al.
Publicado: (2012)

Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib
por: Nagano, Tatsuya, et al.
Publicado: (2011)

Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer
por: Kurata, T, et al.
Publicado: (2004)

Genetic Variant HLA-DRB1*0403 and Therapeutic Response to Disease-Modifying Therapies in Multiple Sclerosis: A Case-Control Study
por: Gomez-Gaitan, Esteban Alejandro, et al.
Publicado: (2023)

Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer
por: Masuda, Noriyuki, et al.
Publicado: (2010)

A phase II trial of dose-dense chemotherapy, followed by surgical resection and/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606)
por: Kunitoh, H, et al.
Publicado: (2010)

Gefitinib for Epidermal Growth Factor Receptor Activated Osteoarthritis Subpopulation Treatment
por: Sun, Heng, et al.
Publicado: (2018)

The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo
por: Akashi, Y, et al.
Publicado: (2007)

Enhanced Antitumor Efficacy of a Combination of CPT‐11, a New Derivative of Camptothecin, and Cisplatin against Human Lung Tumor Xenografts
por: Kudoh, Shinzoh, et al.
Publicado: (1993)

Incidence and outcome of asymptomatic deep vein thrombosis in critically ill patients: a prospective cohort study
por: Echigoya, R, et al.
Publicado: (2015)

Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer
por: Takeuchi, Shinji, et al.
Publicado: (2020)

Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors
por: Blackledge, G, et al.
Publicado: (2004)

Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group
por: Murakami, Haruyasu, et al.
Publicado: (2014)

P.0403 Disticnt effects of SSRIs therapy in patients with the first episode of major depressive disorder/generalized anxiety disorder after COVID-19 disease
por: Bereza, Z., et al.
Publicado: (2021)

Optimal strength and timing of steroids in the management of erlotinib-related skin toxicities in a post-marketing surveillance study (POLARSTAR) of 9909 non-small-cell lung cancer patients
por: Yamazaki, Naoya, et al.
Publicado: (2015)

A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy
por: Tanioka, M, et al.
Publicado: (2013)

Peritoneal and meningeal relapse from lung adenocarcinoma after a response to gefitinib: A case report
por: KURISHIMA, KOICHI, et al.
Publicado: (2013)

Epidermal growth factor receptor mutation in combination with expression of MIG6 alters gefitinib sensitivity
por: Naruo, Yoshimi, et al.
Publicado: (2011)

Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation
por: Nurwidya, Fariz, et al.
Publicado: (2016)

Enhancement of Tumor Radio‐response by Irinotecan in Human Lung Tumor Xenografts
por: Tamura, Kenji, et al.
Publicado: (1997)

Determinants of Myelosuppression in the Treatment of Non‐small Cell Lung Cancer with Cisplatin‐containing Chemotherapy
por: Matsui, Kaoru, et al.
Publicado: (1996)

Losmapimod: A Novel Clinical Drug to Overcome Gefitinib-Resistance
por: Nishimura, Yukio
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4nbk8m4u1i2f54q9sdsnjo66sp